Back to Directory
Last Updated: 05/06/2026
Mestag Therapeutics
Cambridge
Founded 2020
Fibroblast immunology platform targeting cancer and inflammatory disease
Mestag Therapeutics is a clinical-stage biotechnology company developing first-in-class antibody therapies targeting activated fibroblasts to modulate immune responses in cancer and inflammatory disease.
Its lead programme, MST-0312, is a bispecific antibody designed to induce tertiary lymphoid structures in solid tumours to drive anti-tumour immunity.
A second programme targets a stromal inhibitory receptor to address inflammatory conditions including rheumatoid arthritis, IBD, and lupus.